Literature DB >> 29364388

Multiple sclerosis risk perception and acceptance for Brazilian patients.

Denis Bernardi Bichuetti1, Carolina Azze Franco1, Isaac Elias1, Andreia C R Mendonça2, Lorraine Fiama Diniz Carvalho2, Denise Sisterolli Diniz3, Carmen Tur4,5, Mar Tintoré4, Enedina Maria Lobato de Oliveira1.   

Abstract

The perception of multiple sclerosis (MS) severity and risk associated with therapies might influence shared decision making in different countries. We investigated the perception of MS severity and factors associated with risk acceptance in Brazil in 96 patients with relapsing-remitting MS using a standardized questionnaire and compared this with two European cohorts. Multiple sclerosis was perceived as a very severe disease and the risk of developing progressive multifocal leukoencephalopathy due to natalizumab was seen as moderate to high. Seventy-six percent considered a risk of 1:1,000, or higher, an impediment for natalizumab use. Older age was the only variable associated with higher risk acceptance and our patients showed a more conservative profile than German and Spanish patients. Our patients perceived MS severity and progressive multifocal leukoencephalopathy risk similarly to elsewhere, but their willingness to take risks was more conservative. This should be considered when discussing therapeutic options and it might have an impact on guideline adaptations.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29364388     DOI: 10.1590/0004-282X20170167

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  2 in total

1.  Psychosocial Factors Are Associated With Risk Acceptance in Upper Extremity Patients.

Authors:  Amirreza Fatehi; David Ring; Lee M Reichel; Gregg A Vagner
Journal:  Hand (N Y)       Date:  2020-12-24

2.  Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies.

Authors:  Hiba El Masri; Treasure M McGuire; Christine Dalais; Mieke van Driel; Helen Benham; Samantha A Hollingworth
Journal:  J Med Libr Assoc       Date:  2022-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.